The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin

Journal of the American College of Cardiology

Volumn 66, Issue 1, 2015, Pages 74-85

  Patrono, Carlo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

atherothrombosis; colorectal cancer; platelet COX 1; venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PLACEBO; SIMVASTATIN; PROSTAGLANDIN SYNTHASE INHIBITOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTICOAGULATION; BLOOD CLOTTING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHRONIC HEPATITIS B; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DEMENTIA; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; META ANALYSIS (TOPIC); NONHUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; THROMBOCYTE METABOLISM; THROMBOSIS; TISSUE REPAIR; VENOUS THROMBOEMBOLISM; CHEMOPROPHYLAXIS; COLORECTAL NEOPLASMS; DEMENTIA, VASCULAR; DRUG EFFECTS; VASCULAR DISEASES; WOUND HEALING;

ASPIRIN; CHEMOPREVENTION; COLORECTAL NEOPLASMS; CYCLOOXYGENASE INHIBITORS; DEMENTIA, VASCULAR; HUMANS; VASCULAR DISEASES; WOUND HEALING;

EID: 84937395008     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.05.012     Document Type: Review

References (93)

1. G. Born, and C. Patrono Antiplatelet drugs Br J Pharmacol 147 Suppl 1 2006 S241 S251
2. C. Patrono Aspirin as an antiplatelet drug N Engl J Med 330 1994 1287 1294
3. P. Patrignani, P. Filabozzi, and C. Patrono Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects J Clin Invest 69 1982 1366 1372
4. G.A. FitzGerald, J.A. Oates, J. Hawiger, and et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man J Clin Invest 71 1983 676 688
5. C. Patrono, L.A. García Rodríguez, R. Landolfi, and et al. Low-dose aspirin for the prevention of atherothrombosis N Engl J Med 353 2005 2373 2383
6. A. Undas, K. Brummel-Ziedins, and K.G. Mann Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid Thromb Haemost 12 2014 1776 1787
7. M.J. Thun, S.J. Henley, and C. Patrono Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues J Natl Cancer Inst 94 2002 252 266
8. E. Auriel, K. Regev, and A.D. Korczyn Nonsteroidal anti-inflammatory drugs exposure and the central nervous system Handb Clin Neurol 119 2014 577 584
9. A.T. Chan, N. Arber, J. Burn, and et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview Cancer Prev Res (Phila) 5 2012 164 178
10. G. Davì, and C. Patrono Platelet activation and atherothrombosis N Engl J Med 357 2007 2482 2494
11. Coxib and traditional NSAID Trialists' (CNT) Collaboration Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials Lancet 382 2013 769 779
12. C. Patrono, F. Andreotti, H. Arnesen, and et al. Antiplatelet agents for the treatment and prevention of atherothrombosis Eur Heart J 32 2011 2922 2932
13. C. Patrono, C. Baigent, J. Hirsh for the American College of Chest Physicians Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 6 Suppl 2008 199S 233S
14. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
15. C. Patrono Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both or neither? Eur Heart J 34 2013 3403 3411
16. Antithrombotic Trialists' (ATT) Collaboration Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
17. S. Halvorsen, F. Andreotti, J.M. ten Berg, and et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology Working Group on Thrombosis J Am Coll Cardiol 64 2014 319 327
18. U.S. Preventive Services Task Force Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 150 2009 396 404
19. P.O. Vandvik, A.M. Lincoff, J.M. Gore, and et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl 2012 e637S e668S
20. J. Perk, G. De Backer, H. Gohike for the European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur Heart J 33 2012 1635 1701
21. R.S. Hira, K. Kennedy, V. Nambi, and et al. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry J Am Coll Cardiol 65 2015 111 121
22. British Heart Foundation. A Study of Cardiovascular Events in Diabetes (ASCEND) Trial Website. Available at: http://www.ctsu.ox.ac.uk/ascend. Accessed May 7, 2015.
23. G. De Berardis, M. Sacco, V. Evangelista for the ACCEPT-D Study Group Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trials in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins Trials 8 2007 21
24. ASPREE Investigator Group Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial Contemp Clin Trials 36 2013 555 564
25. Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE). Bayer HealthCare. Available at: http://www.arrive-study.com/EN/. Accessed May 7, 2015.
26. Pulmonary Embolism Prevention (PEP) trial Collaborative Group Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial Lancet 355 2000 1295 1302
27. Collaborative overview of randomized trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients BMJ 308 1994 235 243
28. J. Simes, C. Becattini, G. Agnelli for the INSPIRE Study Investigators (International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism) Aspirin for the prevention of recurrent venous thromboembolism. The INSPIRE collaboration Circulation 130 2014 1062 1071
29. R.N. Pinckard, D. Hawkins, and R.S. Farr In vitro acetylation of plasma proteins, enzymes and DNA by aspirin Nature 219 1968 68 69
30. P. Patrignani, S. Tacconelli, E. Piazuelo, and et al. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action J Thromb Haemost 12 2014 1320 1330
31. D. Hawkins, R.N. Pinckard, I.P. Crawford, and et al. Structural changes in human serum albumin induced by ingestion of acetylsalicylic acid J Clin Invest 48 1969 536 542
32. K.R. Bridges, G.J. Schmidt, M. Jensen, and et al. The acetylation of hemoglobin by aspirin. In vitro and in vivo J Clin Invest 56 1975 201 207
33. A.M. Algra, and P.M. Rothwell Effects of regular aspirin on long-term cancer incidence and metastasis: a systemic comparison of evidence from observational studies versus randomised trials Lancet Oncol 13 2012 518 527
34. B.F. Cole, R.F. Logan, S. Halabi, and et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials J Natl Cancer Inst 101 2009 256 266
35. J. Burn, A.M. Gerdes, F. Macrae for the CAPP2 Investigators Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial Lancet 378 2011 2081 2087
36. J. Burn, D.T. Bishop, J.P. Mecklin for the CAPP2 Investigators Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome N Engl J Med 359 2008 2567 2578
37. P.M. Rothwell, J.F. Price, F.G. Fowkes, and et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials Lancet 379 2012 1602 1612
38. P.M. Rothwell, M. Wilson, C.E. Elwin, and et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials Lancet 376 2010 1741 1750
39. P.M. Rothwell, F.G. Fowkes, J.F. Belch, and et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Lancet 377 2011 31 41
40. N.R. Cook, I.M. Lee, S.M. Zhang, and et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial Ann Intern Med 159 2013 77 85
41. R.J. Clarke, G. Mayo, P. Price, and et al. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin N Engl J Med 325 1991 1137 1141
42. C. Patrono, P. Patrignani, and L.A. Garcia Rodriguez Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs J Clin Invest 108 2001 7 13
43. M.J. Thun, E.J. Jacobs, and C. Patrono The role of aspirin in cancer prevention Nat Rev Clin Oncol 9 2012 259 267
44. M. Dovizio, T.J. Maier, S. Alberti, and et al. Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells Mol Pharmacol 84 2013 25 40
45. D. Stegner, S. Dütting, and B. Nieswandt Mechanistic explanation for platelet contribution to cancer metastasis Thromb Res 133 Suppl 2 2014 S149 S157
46. P.M. Rothwell, M. Wilson, J.F. Price, and et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials Lancet 379 2012 1591 1601
47. G. Sitia, R. Aiolfi, P. Di Lucia, and et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B Proc Natl Acad Sci U S A 109 2012 E2165 E2172
48. F. van Kooten, G. Ciabattoni, P.J. Koudstaal, and et al. Increased thromboxane biosynthesis is associated with poststroke dementia Stroke 30 1999 1542 1547
49. A. Douiri, C. McKevitt, E.S. Emmett, A.G. Rudd, and C.D. Wolfe Long-term effects of secondary prevention on cognitive function in stroke patients Circulation 128 2013 1341 1348
50. D. Pan, R.T. Amison, Y. Riffo-Vasquez, and et al. P-Rex and Vav Rac-GEFs in platelets control leukocyte recruitment to sites of inflammation Blood 125 2015 1146 1158
51. R. Amison, C. Page, and S. Pitchford Pharmacological modulation of the inflammatory actions of platelets Handb Exp Pharmacol 210 2012 447 468
52. P. Patrignani, and C. Patrono Cyclooxygenase inhibitors: From pharmacology to clinical read-outs Biochim Biophys Acta 1851 2015 422 432
53. R. Medeiros, M. Kitazawa, G.F. Passos, and et al. Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice Am J Pathol 182 2013 1780 1789
54. J. Claria, and C.N. Serhan Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions Proc Natl Acad Sci U S A 92 1995 9475 9479
55. A.K. Parekh, J.M. Galloway, Y. Hong, and et al. Aspirin in the secondary prevention of cardiovascular disease N Engl J Med 368 2013 204 205
56. T. Grosser, S. Fries, J.A. Lawson, and et al. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin Circulation 127 2013 377 385
57. The Dutch TIA Trial Study Group A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke N Engl J Med 325 1991 1261 1266
58. D.W. Taylor, H.J. Barnett, R.B. Haynes for the ASA and Carotid Endartectomy (ACE) Trial Collaborators Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial Lancet 353 1999 2179 2184
59. CURRENT-OASIS 7 Investigators Dose comparisons of clopidogrel and aspirin in acute coronary syndromes N Engl J Med 363 2010 930 942
60. R.G. Hart, and M.J.G. Harrison Aspirin wars: the optimal dose of aspirin to prevent stroke Stroke 27 1996 585 587
61. L. Wallentin, R.C. Becker, A. Budaj for the PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
62. P. Kohli, J.A. Udell, S.A. Murphy, and et al. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38) J Am Coll Cardiol 63 2014 225 232
63. K.W. Mahaffey, D.M. Wojdyla, K. Carroll for the PLATO Investigators Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial Circulation 124 2011 544 554
64. E.A. Amsterdam, N.K. Wenger, R.G. Brindis, and et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 130 2014 2354 2394
65. J.A. Cairns, M. Gent, J. Singer, and et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial N Engl J Med 313 1985 1369 1375
66. Steering Committee of the Physicians' Health Study Research Group Final report on the aspirin component of the ongoing Physicians' Health Study N Engl J Med 321 1989 129 135
67. P.M. Ridker, N.R. Cook, I.M. Lee, and et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women N Engl J Med 352 2005 1293 1304
68. C. Patrono, G. Ciabattoni, P. Patrignani, and et al. Clinical pharmacology of platelet cyclooxygenase inhibition Circulation 72 1985 1177 1184
69. A.O. Maree, R.J. Curtin, M. Dooley, and et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease J Am Coll Cardiol 46 2005 1258 1263
70. B. Rocca, F. Santilli, D. Pitocco, and et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes J Thromb Haemost 10 2012 1220 1230
71. J.P. Smith, E.V. Haddad, M.B. Taylor, and et al. Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome Hypertension 59 2012 719 725
72. J. DiChiara, K.P. Bliden, U.S. Tantry, and et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study Diabetes 56 2007 3014 3019
73. V. Evangelista, G. de Berardis, L. Totani, and et al. Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin J Thromb Haemost 5 2007 2197 2203
74. F.M. Pulcinelli, L.M. Biasucci, S. Riondino, and et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment Eur Heart J 30 2009 1279 1286
75. A. Dragani, S. Pascale, A. Recchiuti, and et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy Blood 115 2010 1054 1061
76. J.S. Paikin, J. Hirsh, J.S. Ginsberg, and et al. Multiple daily doses of acetyl-salicylic acid (ASA) overcome reduced platelet response to once-daily ASA after CABG: A pilot randomized controlled trial J Thromb Haemost 13 2015 448 456
77. F. Santilli, B. Rocca, R. De Cristofaro, and et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance" J Am Coll Cardiol 53 2009 667 677
78. J.W. Burch, N. Stanford, and P.W. Majerus Inhibition of platelet prostaglandin synthetase by oral aspirin J Clin Invest 61 1978 314 319
79. S. Pascale, G. Petrucci, A. Dragani, and et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target Blood 119 2012 3595 3603
80. G. Spectre, L. Arnetz, C.G. Östenson, and et al. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications Thromb Haemost 106 2011 491 499
81. J.G. Dillinger, A. Drissa, G. Sideris, and et al. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease Am Heart J 164 2012 600 606
82. A. Tefferi, and T. Barbui Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management Am J Hematol 90 2015 162 173
83. C. Patrono, and B. Rocca Drug insight: aspirin resistance-fact or fashion? Nat Clin Pract Cardiovasc Med 4 2007 42 50
84. F. Catella-Lawson, M.P. Reilly, S.C. Kapoor, and et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N Engl J Med 345 2001 1809 1817
85. G. Renda, S. Tacconelli, M.L. Capone, and et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease Clin Pharmacol Ther 80 2006 264 274
86. M.L. Capone, M.G. Sciulli, S. Tacconelli, and et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects J Am Coll Cardiol 45 2005 1295 1301
87. P. Anzellotti, M.L. Capone, A. Jeyam, and et al. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences Arthritis Rheum 63 2011 850 859
88. X. Li, S. Fries, R. Li, and et al. Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs Proc Natl Acad Sci U S A 111 2014 16830 16835
89. G.V. Moukarbel, and D.L. Bhatt Antiplatelet therapy and proton pump inhibition: clinician update Circulation 125 2012 375 380
90. N. Yeomans, A. Lanas, J. Labenz, and et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin Am J Gastroenterol 103 2008 2465 2473
91. A. Lanas, P. Carrera-Lasfuentes, Y. Arguedas, and et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants Clin Gastroenterol Hepatol 13 2015 906 912.e2
92. A. Lanas, and C. Sostres The small bowel, low-dose aspirin and PPIs - should we be concerned? Nat Rev Gastroenterol Hepatol 8 2014 458 460
93. L.A. García Rodríguez, K.J. Lin, S. Hernández-Díaz, and et al. Risk of upper gastro-intestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications Circulation 123 2011 1108 1115